Multiple Myeloma

This publication was created together with leading patient advocates who shared their experiences and insights, in the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These patient organizations provide education and support to promote your health and well-being, and help with practical matters, logistics, and financial and legal concerns.

James D. Bond describes his crucial experience in a clinical trial and thanks the devoted care of his wife Kathleen and the medical team for his continued success in battling this deadly blood cancer.

This special issue was developed together with leading patient advocates, who shared their experiences and insight, with the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These organizations provide education and support for your health and well-being, as well as help with practical matters, logistics, and financial and legal concerns.

In July 2021, the FDA approved a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj), for use in combination with Pomalyst (pomalidomide) and dexamethasone, for adults with multiple myeloma who have received at least 1 previous line of therapy.

In March 2021, the FDA approved a new indication for Sarclisa (isatuximab-irfc), in combination with Kyprolis and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.

Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.

Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.